- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03832192
Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium: a Multi-Site Clinical Study (AvatarHELP)
July 20, 2023 updated by: Victor Wang
Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium, Through Psychosocial Support and Protocol-Driven Interventions Based on the Hospital Elder Life Program: a Multi-Site Clinical Study
Through NINR project 1R44NR017842-01 which preceded the present study, the investigators enhanced the care.coach
avatar platform to incorporate a robust suite of evidence-based protocols based on the Hospital Elder Life Program (HELP), and to leverage an integration with hospital-based electronic medical record (EMR) systems.
In the present study, the investigators seek to validate the efficacy of the new avatar platform, as measured by reduction in falls, delirium, and patient sitter utilization.
Also, the investigators seek to gather patient and outcomes data at a scale sufficient to begin developing machine learning algorithms for intelligent, automatic assignment of protocols to maximize patient engagement and clinical efficacy, and for intelligent, automatic screening of delirium to assist care teams in positive identification of delirium.
Therefore, the present study comprises a two-year randomized between-groups comparison across multiple hospitals to compare outcomes with the new generation of care.coach
avatars as the intervention versus usual care only as the control.
Each study group will be geographically distributed across participating research sites: initially MediSys Health Network's Jamaica Hospital Medical Center in New York, with additional hospitals to join the study over the course of two years.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
301
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 11418
- Jamaica Hospital Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- fall/delirium risk (may be based purely on age at the election of each site, e.g. 65+)
Exclusion Criteria:
- aggression or combativeness with intent to harm self or others
- severe hearing impairment and simultaneous severe vision impairment, despite assistive devices
- no comprehension of either Spanish or English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
|
|
|
Experimental: care.coach Avatar
|
care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incident Delirium Rate
Time Frame: From beginning to end of each participant's inpatient stay, an average of 4 days
|
For each patient without prevalent delirium (each patient who screens negative per the Confusion Assessment Method [CAM] upon study enrollment, which is assumed to be within 24 hours of admission to the hospital unit), Incident Delirium is indicated by any positive CAM screen during the patient's study enrollment period, with CAM screens being performed at least daily (the final CAM screen is assumed to be within 24 hours of discharge from the hospital unit).
Incident Delirium is thus a binary variable (true/false) for each patient, and the rate of Incident Delirium will be compared across study groups, with a lower rate being desirable.
|
From beginning to end of each participant's inpatient stay, an average of 4 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delirium Resolution Rate
Time Frame: From beginning to end of each participant's inpatient stay, an average of 4 days
|
For each patient with prevalent delirium (each patient who screens positive per the Confusion Assessment Method [CAM] upon study enrollment, which is assumed to be within 24 hours of admission to the hospital unit), delirium will be considered resolved if the patient's final CAM screen (which is assumed to be within 24 hours prior to discharge from the hospital unit) indicates no delirium.
Delirium Resolution is thus a binary variable (true/false) for each patient, and the rate of successful Delirium Resolution will be compared across study groups, with a higher rate being desirable.
|
From beginning to end of each participant's inpatient stay, an average of 4 days
|
|
Change in Cognitive Function
Time Frame: From beginning to end of each participant's inpatient stay, an average of 4 days
|
For each patient, the Short Portable Mental Status Questionnaire (SPMSQ) is administered to measure cognitive function (0-10 errors, more errors indicating greater cognitive impairment) upon enrollment and upon dis-enrollment from the study.
Change in Cognitive Function is the difference from the enrollment SPMSQ score to the dis-enrollment SPMSQ score.
Change in Cognitive Function will be compared across study groups, with a larger numerical reduction being desirable.
|
From beginning to end of each participant's inpatient stay, an average of 4 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Delirium Severity
Time Frame: From beginning to end of each participant's inpatient stay, an average of 4 days
|
For each patient screened delirium positive on the Confusion Assessment Method (CAM), the Memorial Delirium Assessment Scale (MDAS) is administered to measure delirium severity upon enrollment and upon dis-enrollment from the study.
Change in Delirium Severity is the difference from the enrollment MDAS score to the dis-enrollment MDAS score.
Change in Delirium Severity will be compared across study groups, with a larger numerical reduction being desirable.
|
From beginning to end of each participant's inpatient stay, an average of 4 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2019
Primary Completion (Actual)
January 7, 2021
Study Completion (Actual)
January 7, 2021
Study Registration Dates
First Submitted
January 29, 2019
First Submitted That Met QC Criteria
February 4, 2019
First Posted (Actual)
February 6, 2019
Study Record Updates
Last Update Posted (Actual)
August 14, 2023
Last Update Submitted That Met QC Criteria
July 20, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R44NR017842-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delirium
-
Alexandria UniversityCompletedClozapine Poisoning | Hypoactive Delirium | Tricyclic Antidepressant Poisoning | Anticholinergic Delirium | Antipsychotic Toxicity | CNS Depression | Procyclidine Induced DeliriumEgypt
-
Efficacy Care R&D LtdHadassah Medical OrganizationUnknownDelirium | Delirium, Cause Unknown | Delirium of Mixed Origin | Delirium Confusional State | Delirium Drug-InducedIsrael
-
Duke UniversityNot yet recruitingDelirium Confusional State | Hyperactive Delirium | Delirium in the Intensive Care Unit | Agitated DeliriumUnited States
-
Imperial College Healthcare NHS TrustRecruitingCardiac Surgery | Intensive Care Unit Delirium | Post Operative DeliriumUnited Kingdom
-
Sengkang General HospitalRecruitingDelirium and Post-operative Cognitive Dysfunction (POCD) | Delirium, Postoperative | Delirium - PostoperativeSingapore
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicCompletedDelirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional StateNorway
-
Universitat de LleidaHospital d'IgualadaNot yet recruitingDelirium in Old Age | Delirium Treatment | Delirium Confusional StateSpain
-
Universidad de SantanderUnknownDelirium of Mixed Origin | Hypoactive Delirium | Hyperactive DeliriumColombia
-
Wonkwang University HospitalCompleted
-
Second Affiliated Hospital of Wenzhou Medical UniversityAffiliated Wenling Hospital of Wenzhou Medical UniversityRecruitingInjection | Delirium in Old Age | Post Operative Delirium | Non-cardiac SurgeryChina
Clinical Trials on care.coach Avatar (HELP-Protocolized)
-
Victor WangDana-Farber Cancer Institute; care.coach corporationRecruitingCancer | Hematopoietic Stem Cell TransplantationUnited States